Abstract
Since its beginnings in the early 1970s, clinical nuclear cardiology has evolved substantially, gaining both technical sophistication and enhanced imaging capabilities. Importantly, in parallel to these developments, an extensive literature supporting the clinical and cost-effectiveness of this modality has developed. Today, state-of-the-art nuclear cardiology allows for the objective measurement of both myocardial function and relative regional myocardial perfusion at rest and stress, providing accurate risk assessment in a wider variety of patient subsets. This chapter will highlight stress myocardial perfusion single-photon emission CT (SPECT), which currently comprises approximately 95 % of the procedures performed in this field.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Myocardial Perfusion
- Nuclear Cardiology
- Invasive Coronary Angiography
- Myocardial Perfusion SPECT
- Transient Ischemic Dilation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Since its beginnings in the early 1970s, clinical nuclear cardiology has evolved substantially, gaining both technical sophistication and enhanced imaging capabilities. Importantly, in parallel to these developments, an extensive literature supporting the clinical and cost-effectiveness of this modality has developed. Today, state-of-the-art nuclear cardiology allows for the objective measurement of both myocardial function and relative regional myocardial perfusion at rest and stress, providing accurate risk assessment in a wider variety of patient subsets. This chapter will highlight stress myocardial perfusion single-photon emission CT (SPECT), which currently comprises approximately 95 % of the procedures performed in this field.
The chapter is organized as follows: first, there is a discussion of the general concepts of risk assessment in chronic coronary artery disease (CAD), including evidence for the cost-effective characteristics of stress myocardial perfusion SPECT (MPS) compared with alternative strategies without MPS, as well as data supporting the selection of MPS in specific patient populations. This discussion is followed by the largest section of the chapter, which deals with the current evidence for the use of MPS for risk stratification. This is followed by a brief section dealing with the importance of parameters other than stress myocardial perfusion defects that impact post-MPS patient risk and estimates of risk. The final portion of this chapter deals with the role of MPS in identifying whether patients will have enhanced survival with medical therapy versus revascularization based on the results of the MPS study. In this context, the role of gated SPECT ejection fraction and the potential importance of validated scores to estimate patient risk will be mentioned as well. The conclusion of the chapter addresses the need for the integration of SPECT results with other clinical data in guiding inpatient management decisions.
This chapter will be limited to the consideration of stable patients with known or suspected chronic CAD and will focus primarily on stress myocardial perfusion abnormalities, since myocardial viability (predominantly assessed by resting studies) is addressed in another chapter.
The main use of nuclear cardiology studies for guiding management decisions is determining which patients with suspected or known coronary artery disease require catheterization with consideration of revascularization. In patients who have “limiting” chest pain symptoms, which despite medical therapy affect their well being, nuclear cardiology studies play a limited role; they are chiefly useful for identifying the culprit coronary lesion and determining which vessel or vessels might be most appropriate for revascularization. Since revascularization has been shown to relieve anginal symptoms in patients with CAD, it would not be cost effective to study all patients with limiting symptoms with MPS and direct invasive coronary angiography is generally indicated.
If revascularization is being considered for purposes of improving prognosis, MPS can be helpful in determining whether the patient’s risk is high enough to warrant revascularization. Risk stratification is the most rapidly growing area of application of MPS. The use of MPS for this purpose provides a widely accepted new paradigm in patient management, which is endorsed by clinical guidelines. A risk-based approach to patients with known or suspected CAD is well suited to the current environment, in which cost containment is of great importance and in which dramatic improvements in medical therapy have been developed. In contrast, the approach focusing on simple diagnosis, in which patients with suspected disease undergo invasive coronary angiography and then are frequently revascularized based on coronary anatomic findings, has been shown to be less cost effective. With the risk-based approach, the focus is not on predicting who has anatomic CAD but on identifying and separating patients at higher risk for a major adverse cardiac event from those who are at lower risk.
Pathophysiologic Basis for Risk Assessment in Myocardial Perfusion SPECT
The basis for the power of nuclear testing for risk stratification is found in the fact that the major determinants of prognosis in CAD can be assessed by measurements of stress-induced perfusion or function. These measurements include the amount of infarcted myocardium, the amount of jeopardized myocardium (supplied by vessels with hemodynamically significant stenosis), and the degree of jeopardy (tightness of the individual coronary stenosis). An additional important factor in prognostic assessment is the stability (or instability) of the CAD process. This last consideration may help explain what appears to be a clinical paradox: Nuclear tests, which in general are expected to be positive only in the presence of hemodynamically significant stenosis, are associated with a very low risk of either cardiac death or nonfatal myocardial infarction when normal. In contrast, it has been observed that most myocardial infarctions occur in regions with premyocardial infarction coronary plaques causing less than 50 % of stenosis [1, 2]. It has been postulated that this paradox may be explained by the different response to stress of mild stenosis associated with stable and unstable plaques. For example, it has been shown that mild coronary narrowings associated with unstable plaque manifest a vasoconstrictive response to acetylcholine stimulation due to abnormal endothelial function, whereas stable, mild coronary lesions respond to acetylcholine with vasodilation [1]. It is possible that factors released during exercise or vasodilator stress may be similar to acetylcholine in terms of stimulation of a differential endothelial response in stable and unstable plaques. Thus, beyond the ability to define anatomic stenosis, nuclear tests (by virtue of their assessment of physiology) would be able to discern abnormalities of endothelial function associated with high risk, even in the absence of significant stenosis.
Differentiating Outcome Type by Nuclear Test Results
Recent evidence in large patient cohorts has revealed that factors estimating the extent of left ventricular dysfunction (left ventricular ejection fraction, the extent of infarcted myocardium, transient ischemic dilation of the left ventricle, and increased lung uptake) are excellent predictors of cardiac mortality. In contrast, measurements of inducible ischemia are better predictors of the development of acute ischemic syndromes. These include exertional symptoms and electrocardiographic changes, as well as the extent of perfusion defect reversibility and stress-induced ventricular dyssynergy. Several recent reports have shown that nuclear testing yields an incremental prognostic value over clinical information with respect to cardiac death or the combination of cardiac death and nonfatal myocardial infarction as isolated endpoints. By understanding how clinical information and nuclear test markers can be used to estimate varying outcomes, it is now possible to tailor therapeutic decision making for an individual patient based on the combination of clinical factors and nuclear scan results. For example, a patient with severe perfusion abnormalities on their stress imaging may have a five- to ten-fold higher likelihood of cardiac death compared with a patient with a normal MPS. If the defects are stress induced (reversible), therapies known to improve survival might be chosen in order to result in an optimized outcome for that patient.
References
Hasdai D, Gibbons RJ, Holmes Jr DR, et al. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997;96:3390–5.
Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol. 1986;7:464–71.
Garcia EV. Quantitative myocardial perfusion single-photon emission computed tomographic imaging: quo vadis? (Where do we go from here?). J Nucl Cardiol. 1994;1:83–93.
Sharir T, Germano G, Waechter PB, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. II: validation and diagnostic yield. J Nucl Med. 2000;41:720–7.
Germano G, Kavanagh P, Waechter P, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. I: technical principles and reproducibility. J Nucl Med. 2000;41:712–9.
Berman DS, Abidov A, Kang X, et al. Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion SPECT interpretation. J Nucl Cardiol. 2004;11:414–23.
Berman DS, Kiat H, Friedman JD, et al. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study. J Am Coll Cardiol. 1993;22:1455–64.
Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardialsegmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539–42.
Berman DS, Kang X, Gransar H, et al. Quantitative assessment of myocardialperfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis. J Nucl Cardiol. 2009;16(1):45–53.
Slomka PJ, Nishina H, Berman DS, et al. Automated quantification of myocardial perfusion SPECT using simplified normal limits. J Nucl Cardiol. 2005;12:66–77.
Mazzanti M, Germano G, Kiat H, et al. Identification of severe and extensive coronary artery disease by automatic measurement of transient ischemic dilation of the left ventricle in dual-isotope myocardial perfusion SPECT. J Am Coll Cardiol. 1996;27:1612–20.
Shaw LJ, Hachamovitch R, Berman DS, et al. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. J Am Coll Cardiol. 1999;33:661–9.
Matzer L, Kiat H, Van Train K, et al. Quantitative severity of stress thallium-201 myocardial perfusion single-photon emission computed tomography defects in one-vessel coronary artery disease. Am J Cardiol. 1993;72:273–9.
Sharir T, Bacher-Stier C, Dhar S, et al. Identification of severe and extensivecoronary artery disease by postexercise regional wall motion abnormalities inTc-99m sestamibi gated single-photon emission computed tomography. Am J Cardiol. 2000;86:1171–5.
Borges-Neto S, Shaw LK, Tuttle RH. Incremental prognostic power of SPECT myocardial perfusion imaging in patients with known or suspected coronary artery disease. Am J Cardiol. 2005;95:182–8.
Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol. 1995;26:639–47 (published erratum appears in J Am Coll Cardiol. 1996;27:756).
Christian TF, Miller TD, Bailey KR, Gibbons RJ. Exercise tomographic thallium-201 imaging in patients with severe coronary artery disease and normal electrocardiograms. Ann Intern Med. 1994;121:825–32.
Hachamovitch R, Berman DS, Kiat H, et al. Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and costeffectiveness. Circulation. 2002;105:823–9.
Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging). Circulation. 2003;108:1404–18.
Berman DS, Hachamovitch R, Shaw LJ, et al. Nuclear cardiology. In: Fuster V, O’Rourke RA, Roberts R, et al., editors. Hurst’s the heart. 11th ed. New York: McGraw-Hill Companies; 2004. p. 563–97.
Ladenheim ML, Kotler TS, Pollock BH, et al. Incremental prognostic power of clinical history, exercise electrocardiography and myocardial perfusion scintigraphy in suspected coronary artery disease. Am J Cardiol. 1987;59:270–7.
Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation. 1996;93:905–14.
Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;97:535–43.
Marwick TH, Shaw LJ, Lauer MS, et al. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group. Am J Med. 1999;106:172–8.
Sharir T, Germano G, Kang X, et al. Prognostic value of post-stress left ventricular volume and ejection fraction by gated myocardial perfusion single photon emission computed tomography in women: gender related differences in normal limits and outcome [abstract]. Circulation. 2002;106:II–523.
Zellweger MJ, Lewin HC, Lai S, et al. When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. J Am Coll Cardiol. 2001;37:144–52.
Sharir T, Germano G, Kang X, et al. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction. J Nucl Med. 2001;42:831–7.
Travin MI, Heller GV, Johnson LL, et al. The prognostic value of ECG-gated SPECT imaging in patients undergoing stress Tc-99m sestamibi myocardialperfusion imaging. J Nucl Cardiol. 2004;11:253–62.
Thomas GS, Miyamoto MI, Morello AP, et al. Technetium99m based myocardial perfusion imaging predicts clinical outcome in the community outpatient setting: the nuclear utility in the community (“nuc”) study. J Am Coll Cardiol. 2004;43:213–23.
Heller GV, Herman SD, Travin MI, et al. Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions. J Am Coll Cardiol. 1995;26:1202–8.
Kang X, Berman DS, Lewin HC, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J. 1999;138(6 Pt 1):1025–32.
Giri S, Shaw LJ, Murthy DR, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation. 2002;105:32–40.
Vanzetto G, Ormezzano O, Fagret D, et al. Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1137 patients with 6-year follow-up. Circulation. 1999;100:1521–7.
Diamond GA, Staniloff HM, Forrester JS, et al. Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary artery disease. J Am Coll Cardiol. 1983;1(2 Pt 1):444–55.
Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27:1954–61.
Sharir T, Berman DS, Lewin HC, et al. Incremental prognostic value of rest-redistribution Tl-201 single-photon emission computed tomography. Circulation. 1999;100:1964–70.
Hachamovitch R, Hayes SW, Friedman JD, et al. Stress myocardial perfusion SPECT is clinically effective and cost-effective in risk-stratification of patients with a high likelihood of CAD but no known CAD. J Am Coll Cardiol. 2004;43:200–8.
Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines forthe management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on PracticeGuidelines (Committee on Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 1999;33:2092–197.
Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardialperfusion defects on radionuclide imaging. Circulation. 1999;100:2140–5.
Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11:171–85.
Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.
Beller GA. The epidemics of obesity and type 2 diabetes: Implications for noninvasive cardiovascular imaging. Journal of Nuclear Cardiology 2004; 11(2):105–6
Stratmann HG, Tamesis BR, Younis LT, et al. Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. Am J Cardiol. 1994;73:647–52.
Shaw L, Chaitman BR, Hilton TC, et al. Prognostic value of dipyridamole thallium-201 imaging in elderly patients [comment]. J Am Coll Cardiol. 1992;19:1390–8.
Calnon DA, McGrath PD, Doss AL, et al. Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomographymyocardial perfusion imaging: stratification of a high-risk population [comment]. J Am Coll Cardiol. 2001;38:1511–7.
Amanullah AM, Kiat H, Friedman JD, Berman DS. Adenosine technetium-99m sestamibi myocardial perfusion SPECT in women: diagnostic efficacy in detection of coronary artery disease. J Am Coll Cardiol. 1996;27:803–9.
Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? J Am Coll Cardiol. 2003;41:1329–40.
Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900–7.
Berman DS, Kang X, Hayes SW, et al. Adenosine myocardial perfusion single-photon emission computed tomography in women compared with men. Impact of diabetes mellitus on incremental prognostic value and effect on patient management. J Am Coll Cardiol. 2003;41:1125–33.
Hachamovitch R, Rozanski A, Hayes SW, et al. Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary? J Nucl Cardiol. 2006;13:768–78.
He ZX, Hedrick TD, Pratt CM, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia. Circulation. 2000;101:244–51.
Iskander S, Iskandrian AE. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol. 1998;32:57–62.
Abidov A, Hachamovitch R, Rozanski A, et al. Prognostic implications of atrial fibrillation in patients undergoing myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol. 2004;44:1062–70.
Shaw LJ, Hendel RC, Cerqueira M, et al. Ethnic differences in the prognostic value of stress technetium-99m tetrofosmin gated single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005;45:1494–504.
Matsuo S, Nakajima K, Horie M, J-ACCESS Investigators, et al. Prognostic value of normal stress myocardial perfusion imaging in Japanese population. Circ J. 2008;72:611–7.
Zellweger MJ, Hachamovitch R, Kang X, et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Euro Heart J. 2004;25:543–50.
Abidov A, Hachamovitch R, Hayes SW, et al. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation. 2003;107:2894–9.
Hachamovitch R, Hayes SW, Friedman JD, et al. A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. J Am Coll Cardiol. 2005;45:722–9.
Hachamovitch R, Friedman JD, Cohen I, et al. Is there a referral bias against revascularization of patients with reduced LV ejection fraction? Influence of ejection fraction and inducible ischemia on post-SPECT management of patients without history of CAD. J Am Coll Cardiol. 2003;42:1286–94.
Hachamovitch R, Di Carli MF. Methods and limitations of assessing newnoninvasive tests: part I: anatomy-based validation of noninvasive testing. Circulation. 2008;117:2684–90.
Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.
Berman DS, Wong ND, Gransar H, et al. Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. J Am Coll Cardiol. 2004;44:923–30.
Rozanski A, Gransar H, Wong ND, et al. Clinical outcomes after both coronary calcium scanning and exercise myocardial perfusion scintigraphy. J Am Coll Cardiol. 2007;49:1352–61.
Schenker MP, Dorbala S, Hong EC, et al. Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study. Circulation. 2008;117:1693–700.
Anand DV, Lim E, Hopkins D, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006;27:713–21.
Blumenthal RS, Becker DM, Yanek LR, et al. Comparison of coronary calcium and stress myocardial perfusion imaging in apparently healthy siblings of individuals with premature coronary artery disease. Am J Cardiol. 2006;97:328–33.
Rozanski A, Gransar H, Wong ND, et al. Use of coronary calcium scanning for predicting inducible myocardial ischemia: Influence of patients’ clinical presentation. J Nucl Cardiol. 2007;14:669–79.
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.
Anand DV, Lim E, Raval U, et al. Prevalence of silent myocardial ischemia in asymptomatic individuals with subclinical atherosclerosis detected by electron beam tomography. J Nucl Cardiol. 2004;11:450–7.
Wong ND, Rozanski A, Gransar H, et al. Metabolic syndrome and diabetes are associated with an increased likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis. Diabetes Care. 2005;28:1445–50.
Berman DS, Hayes S, Friedman J, et al. Normal myocardial perfusion SPECT does not imply the absence of significant atherosclerosis [abstract]. Circulation. 2003;108:IV–562.
Berman DS, Hachamovitch R, Shaw LJ, et al. Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: noninvasive risk stratification and a conceptual framework for the selection of noninvasive imaging tests in patients with known or suspected coronary artery disease. J Nucl Med. 2006;47:1107–18.
Acknowledgment
The authors gratefully acknowledge the valuable assistance of Xingping Kang, MD in the preparation of this chapter.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hachamovitch, R., Berman, D., Shaw, L.J., Germano, G., Mieres, J.H. (2013). Risk Stratification and Patient Management. In: Dilsizian, V., Narula, J. (eds) Atlas of Nuclear Cardiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5551-6_7
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5551-6_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5549-3
Online ISBN: 978-1-4614-5551-6
eBook Packages: MedicineMedicine (R0)